Advanced search
Publication Cover
Leukemia & Lymphoma Volume 44, 2003 - Issue 1
Submit an article Journal homepage
54
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013

Richard T. Silver Weill Medical College of Cornell University, Division of Hematology Oncology, 525 E. 68th St Box 581 New York, NY 10021, USA
,
Bercedis L. Peterson CALGB Statistical Center, Durham, NC, USA
,
Ted P. Szatrowski Weill Medical College of Cornell University, Division of Hematology Oncology, 525 E. 68th St Box 581 New York, NY 10021, USA
,
Bayard L. Powell Wake Forest University School of Medicine, Winston Salem, NC, USA
,
Wendy Stock University of Chicago, Chicago, IL, USA
,
Andrew J. Carroll University of Alabama, Birmingham, AL, USA
,
Clara D. Bloomfield The Ohio State University, Columbus, OH, USA
,
Charles A. Schiffer Wayne State University, Detroit, MI, USA
&
Richard A. Larson Cancer and Leukemia Group B, Chicago, IL, USA
 show all
Pages 39-48 | Published online: 01 Jul 2009

  • Guillot, F., Chastang, C., Michallet, et al. (1997) "Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French chronic myeloid leukemia study group", N. Engl. J. Med. 337, 223-229.
  • The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1998) "Long-term follow-up of the Italian trial of interferon alfa versus conventional therapy in chronic myeloid leukemia". Blood 98, Sept 1: 92(5), pp. 1541-1548.
  • Kantarjian, H.M., Keating, M.J., Estey, E.H., et al. (1992) "Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alfa and low-dose cytarabine", J. Clin. Oncol. 10, 772-778.
  • Arthur, C. (1993) "Combined interferon alfa-2b and cytosine arabinoside as first time treatment for chronic myeloid leukemia", Acta Haematol. 89(Suppl. 1), 15-21.
  • Thaler, J., Hilbe, W., Apfelbeck, U., et al. (1997) "Interferon alpha 2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study", Leuk. Res. 21, 75-80.
  • Sokal, J.E., Ledng, S.S. and Gomez, G.A. (1987) "Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia". Cancer 59, 197-202.
  • Silver, R.T., Benn, P., Szatrowski, T.P., et al. (1990) "Infusional cytosine arabinoside (ara-C) and recombinant interferon alfa (rIFNa) for the treatment of chronic myeloid leukemia", Proc. Am. Soc. Clin. Oncol. 9, 209. Abstract.
  • Spriggs, D., Griffen, J., Wisch, J., et al. (1985) "Clinical pharmacology of low dose cytosine arabinoside". Blood 65, 1087-1089.
  • Stock, W., Westbrook, C.A., Peterson, B., et al. (1997) "Value of molecular monitoring during the treatment of chromic myeloid leukemia. A cancer and leukemia group B study". J. Clin. Oncol. 15, 26-36.
  • Hensley, M.L., Peterson, B., Silver, R.T., Larson, R.A., Schiffer, C.A. and Szatrowski, T.P. (2000) "Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013", J. Clin. Oncol. 18, 1301-1308.
  • Silver, R.T. (1997) "Chronic myeloid leukemia", In: Holland, J.F., Frei, E., Bast, R.C., Kufe, D.W., Morton, D.L. and Weichselbaum, R.R., eds. Cancer Medicine, 4th Ed. (William & Wilkins, Baltimore, MD), p. 2651.
  • Karanas, A. and Silver, R.T. (1968) "Characteristics of the terminal phase of chronic granulocytic leukemia", Blood 32(3), 445-459.
  • Ozer, H., George, S.L., Schiffer, C.A., et al. (1993) "Prolonged subcutaneous administration of recombinant alfa 2B interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival. Cancer and Leukemia Group B study 8583", Blood 82, 2975-2984.
  • Kaplan, E.L. and Meier, P. (1958) "Nonparametric estimation from incomplete observations", J. Am. Statist. Assoc. 43, 457-481.
  • Pepe, M.S. and Mori, M. (1993) "Kaplan-Meier marginal or conditional probability curves in summarizing competing risks failure time date", Statist. Med. 12, 737-751.
  • Sokal, J.E., Cox, E.B., Baccarani, M., et al. (1984) "Prognostic discrimination in "good risk" chronic granulocytic leukemia". Blood 63, 789-799.
  • Hasford, J., Pfirrman, M., Hehlmann, R., Allan, N.C., et al. (1998) "A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa". J. Natl Cancer Inst. 90, 850-858.
  • Silver, R.T., Woolf, S.H., Hehlmann, R., et al. (1999) "An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneie bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American society of hematology", Blood 94, 1517-1536.
  • Baccarani, M. (2001) "Non-transplant treatment options for patients with newly diagnosed chronic myeloid leukemia", In: Schechter, E., ed. Hematology (American Society of Hematology Education Book, Table 8. pp. 98-103.
  • Baccarani, M. and Guillot, F., Personal Communication.
  • Shepherd, P., Kluin-Nelemans, Richards, S., et al. (2001) "A randomized comparison of low or high dose IFN-a in newly diagnosed CML patients shows no difference in major cytogenetic response rate or survival between the two groups. Results of MRC CML V & HOVON 20 trials", Blood 98(Suppl. 1), 11, Abst. 3034.
  • Faderl, S., Talpaz, M., Kantarjian, H.M. and Estrov, Z. (1999) "Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myeloid leukemia be used in clinical decision making?", Blood 93, 2755-2759.
  • Uhr, J., Scheuermann, R.H., Street. N.E., et al. (1997) "Cancer dormancy: opportunities for new therapeutic approaches", Nature Med. 3, 505-509.
  • Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M. and Druker, B. (2002) "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia", N. Engl. J. Med. 346, 645-652.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.